Form 4: Ocular Therapeutix COO Sells Shares for Tax Obligations

Ocular Therapeutix's Chief Operating Officer, Donald Notman, sold shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Donald Notman, Chief Operating Officer of Ocular Therapeutix, Inc. (OCUL), reported sales of common stock.
• On February 2, 2026, 5,455 shares were sold at a weighted average price of $9.14 per share, ranging from $9.0565 to $9.3217.
• On February 4, 2026, an additional 6,035 shares were sold at a weighted average price of $8.54 per share, ranging from $8.4377 to $8.6769.
• These sales were non-discretionary, executed pursuant to a durable automatic sales instruction letter dated May 13, 2022.
• The purpose of the sales was to satisfy tax withholding obligations associated with the vesting of restricted stock units on January 30, 2026, and February 3, 2026.
• Following these transactions, Donald Notman beneficially owns 377,802 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sales are routine, non-discretionary transactions for tax purposes, which do not reflect a change in the executive's confidence in the company's prospects.

Positives

• The sales were non-discretionary, indicating they were not a reflection of management's view on the company's future prospects but rather a routine tax-related event.

Negatives

• The transactions resulted in a reduction of insider ownership by 11,490 shares, which, while for tax purposes, still decreases the direct stake of a key executive.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are a common and routine practice among executives who receive equity compensation, particularly restricted stock units. These sales are typically pre-arranged and non-discretionary, designed to meet tax obligations upon vesting, and are generally not indicative of an executive's sentiment towards the company's stock performance.

Management Changes

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, but the non-discretionary nature of the sale mitigates concerns about management's confidence.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Keywords

OCUL, Ocular Therapeutix, Donald Notman, Insider Trading, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units, Corporate Officer